MSF
Treatment Action Group, Partners in Health and Medécins Sans Frontières wrote an open letter to Johnson & Johnson seeking clarification on its deal with Global Drug Facility to supply generic versions of TB drug bedaquiline and also reiterated its demand for a public announcement of non-enforcement of secondary patents on bedaquiline in all low-, lower-middle, https://upper-middle, and high-TB- or MDR-TB-burden countries.
Keywords